metastatic castration sensitive prostate cancer pipeline insight
"Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Metastatic Castration-Sensitive Prostate Cancer market. A detailed picture of the Metastatic Castration-Sensitive Prostate Cancer pipeline landscape is provided, which includes the disease overview and Metastatic Castration-Sensitive Prostate Cancer treatment guidelines. The assessment part of the report embraces in-depth Metastatic Castration-Sensitive Prostate Cancer commercial assessment and clinical assessment of the Metastatic Castration-Sensitive Prostate Cancer pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Metastatic Castration-Sensitive Prostate Cancer collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Unlock comprehensive insights! Click Here to Purchase the Full Market Report @ Metastatic Castration-Sensitive Prostate Cancer Treatment Market Size
Metastatic Castration-Sensitive Prostate Cancer of Pipeline Development Activities
The report provides insights into:
- All of the companies that are developing therapies for the treatment of Metastatic Castration-Sensitive Prostate Cancer with aggregate therapies developed by each company for the same.
- Different therapeutic candidates segmented into early-stage, mid-stage and late stage of development for the Metastatic Castration-Sensitive Prostate Cancer treatment.
- Metastatic Castration-Sensitive Prostate Cancer key players involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of Metastatic Castration-Sensitive Prostate Cancer market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third-party sources, etc.
Get More Insights of this Report @ Prostate Cancer Treatment Market Size
Metastatic Castration-Sensitive Prostate Cancer Recent Developments
- In September 2024, Ipsen announced that the Phase III CONTACT-02 trial for Cabometyx® and atezolizumab in mCRPC showed a non-significant improvement in overall survival but met the progression-free survival (PFS) endpoint.
- In September 2024, Foundation Medicine received FDA approval for FoundationOne®CDx and Liquid CDx as companion diagnostics for Lynparza® in BRCA-mutated mCRPC.
- In July 2024, the ARANOTE trial showed that NUBEQA® plus ADT significantly improved radiological PFS in metastatic hormone-sensitive castrate-resistant prostate cancer (mHSPC).
- In July 2024, the FDA granted fast-track designation to SYNC-T SV-102 for metastatic castrate-resistant prostate cancer (mCRPC).
- In June 2024, Kangpu Biopharmaceuticals received FDA approval for a Phase II/III trial of KPG-121 with Abiraterone for mCRPC.
- In May 2024, Fusion Pharmaceuticals began the Phase 2 AlphaBreak trial of FPI-2265 in mCRPC patients.
- In April 2024, Astellas Pharma received European approval for XTANDI™ in high-risk biochemical recurrent non-metastatic hormone-sensitive prostate cancer (nmHSPC).
- In April 2024, FibroGen announced positive Phase 1 trial data for FG-3246 in mCRPC.
- On November 16, 2023, the FDA approved enzalutamide (Xtandi) for non-metastatic castration-sensitive prostate cancer (nmCSPC) with high-risk biochemical recurrence.
Metastatic Castration-Sensitive Prostate Cancer Analytical Perspective by DelveInsight
In-depth Metastatic Castration-Sensitive Prostate Cancer Commercial Assessment of products
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, and acquisition deal value trends. The report also covers company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form in a detailed manner.
Metastatic Castration-Sensitive Prostate Cancer Clinical Assessment of products
The report comprises of comparative clinical assessment of products by development stage, product type, and route of administration, molecule type, and MOA type across this indication.
Take Your Research to the Next Level! Click Here to Get Access to the Full Epidemiology Report @ Metastatic Castration-Sensitive Prostate Cancer Prevalence
Scope of the Report
- The Metastatic Castration-Sensitive Prostate Cancer report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Metastatic Castration-Sensitive Prostate Cancer across the complete product development cycle, including all clinical and nonclinical stages.
- It comprises of detailed profiles of Metastatic Castration-Sensitive Prostate Cancer therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
- Detailed Metastatic Castration-Sensitive Prostate Cancer research and development progress and trial details, results wherever available, are also included in the pipeline study.
- Coverage of dormant and discontinued pipeline projects along with the reasons if available across Metastatic Castration-Sensitive Prostate Cancer.
Report Highlights
- A better understanding of disease pathogenesis contributing to the development of novel therapeutics for Metastatic Castration-Sensitive Prostate Cancer.
- In the coming years, the Metastatic Castration-Sensitive Prostate Cancer market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
- The companies and academics that are working to assess challenges and seek opportunities that could influence Metastatic Castration-Sensitive Prostate Cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A detailed portfolio of major pharma players who are involved in fueling the Metastatic Castration-Sensitive Prostate Cancer treatment market. Several potential therapies for Metastatic Castration-Sensitive Prostate Cancer are under investigation. With the expected launch of these emerging therapies, it is expected that there will be a significant impact on the Metastatic Castration-Sensitive Prostate Cancer market size in the coming years.
- Our in-depth analysis of the pipeline assets (in early-stage, mid-stage and late stage of development for the treatment of Metastatic Castration-Sensitive Prostate Cancer) includes therapeutic assessment and comparative analysis. This will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Key Questions
- What are the current options for Metastatic Castration-Sensitive Prostate Cancer treatment?
- How many companies are developing therapies for the treatment of Metastatic Castration-Sensitive Prostate Cancer?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Metastatic Castration-Sensitive Prostate Cancer?
- How many Metastatic Castration-Sensitive Prostate Cancer emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Metastatic Castration-Sensitive Prostate Cancer?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Metastatic Castration-Sensitive Prostate Cancer market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Metastatic Castration-Sensitive Prostate Cancer?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Metastatic Castration-Sensitive Prostate Cancer therapies?
- What are the clinical studies going on for Metastatic Castration-Sensitive Prostate Cancer and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Metastatic Castration-Sensitive Prostate Cancer?
- How many patents are granted and pending for the emerging therapies for the treatment of Metastatic Castration-Sensitive Prostate Cancer?
Stay Updated with us for Recent Articles
